The European Medicines Agency (EMA) said it has found a possible link between the Coronavirus jab, developed by British-Swedish pharmaceutical AstraZeneca and the Oxford University and the occurrence of blood clots.
“EMA’s safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria,” the Amsterdam Based company said in a statement issued on Wednesday.
“However, the PRAC has confirmed that the benefit…
This story is part of New Europe’s Premium content.
| To Read the Full Story, Subscribe or Sign In from the ↑ Top of the Page ↑ |
In this article:
